Obinutuzumab

Category: Cancer

Obinutuzumab Overview

Obinutuzumab (called afutuzumab until 2009,[1] originally GA101) is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Contents...

Read more Obinutuzumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Obinutuzumab

Recent Obinutuzumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Obinutuzumab or a similar ingredient: (1 result)

• GAZYVA Obinutuzumab